Affiliation:
1. Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd.
2. Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development
Abstract
AbstractA cost-effective, scalable, high-yielding, and commercially viable synthesis of 4-bromo-1,2-dimethyl-1H-imidazole (1), an important building block to construct various bioactive molecules has been established. The main feature of this method includes the selection of appropriate starting material 1,2-dimethyl-1H-imidazole in which the existing issue of regioisomer formation is circumvented and the selective debromination is accomplished by using isopropyl magnesium chloride.
Subject
Organic Chemistry,Materials Science (miscellaneous),Biomaterials,Catalysis